REP 2165

Drug Profile

REP 2165

Alternative Names: REP 2165 magnesium chelate; REP 2165-Mg

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator REPLICor
  • Class Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Preclinical Hepatitis D

Most Recent Events

  • 20 Apr 2017 Updated pharmacodynamics data from phase II REP 401 trial in Hepatitis B released by REPLICor
  • 20 Feb 2017 Pharmacodynamics data from phase II REP 401 trial in Hepatitis B released by REPLICor
  • 09 Nov 2015 REPLICor receives patent allowance for methods of combination therapy using immunotherapeutic agents and agents that lower serum HBsAg in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top